10-K: Shuttle Pharmaceuticals Holdings Reports Full Year 2024 Results, Cites Going Concern Risk

Shuttle Pharmaceuticals Holdings reports a net loss of $9.1 million for 2024 and acknowledges substantial doubt about its ability to continue as a going concern without additional financing.

Summary

• Shuttle Pharmaceuticals Holdings, a clinical-stage pharmaceutical company, reported its financial results for the year ended December 31, 2024.
• The company incurred a net loss of approximately $9.1 million and had no revenues for the year.
• As of December 31, 2024, the company's working capital was approximately $0.7 million.
• The company acknowledges that its ability to continue as a going concern is dependent on raising additional equity or debt financing.
• The company is developing Ropidoxuridine, a Phase II clinical-stage radiation sensitizer, and a platform of HDAC inhibitors.
• In January 2024, the FDA issued a Safe to Proceed letter for the Phase II study of Ropidoxuridine.
• Seventeen patients have enrolled in the Phase II clinical study as of February 24, 2025, with half completing all seven courses of treatment.
• The company is also developing two preclinical, prostate cancer-oriented diagnostics assets.
• The company's common stock failed to maintain a minimum closing bid price of $1.00 per share, as required for continued listing on The Nasdaq Capital Market.
• The company has until June 30, 2025, to regain compliance with the Minimum Bid Price Requirement.
• The company also received a letter from Nasdaq notifying the company that it is no longer in compliance with the minimum stockholders equity requirement for continued listing on the Nasdaq Capital Market.
• The company has until March 10, 2025, to regain compliance with the minimum stockholders equity standard.

Sentiment

Score: 3

Explanation: The document presents a concerning financial situation with a significant net loss, going concern risk, and Nasdaq listing compliance issues. While there is some progress in clinical trials, the overall outlook is negative.

Positives

• The company received a Safe to Proceed letter from the FDA for the Phase II study of Ropidoxuridine.
• Seventeen patients have enrolled in the Phase II clinical study as of February 24, 2025, with half completing all seven courses of treatment.

Negatives

• The company incurred a net loss of approximately $9.1 million and had no revenues for the year ended December 31, 2024.
• As of December 31, 2024, the company's working capital was approximately $0.7 million.
• The company's common stock failed to maintain a minimum closing bid price of $1.00 per share, as required for continued listing on The Nasdaq Capital Market.
• The company is not in compliance with the minimum stockholders equity requirement for continued listing on the Nasdaq Capital Market.

Risks

• The company's ability to continue as a going concern is dependent on raising additional equity or debt financing.
• The company may be unable to regain compliance with Nasdaq listing requirements, potentially leading to delisting.
• The company's internal controls over financial reporting were deemed to be inadequate, which could cause financial reporting to be unreliable.
• The company faces competition from entities that have developed or may develop product candidates for its target disease indications.
• The company's product candidates are in the early stages of development and may fail in development or suffer delays.

Future Outlook

The company anticipates needing to seek additional funding through public or private equity or debt financings or other sources, such as through a rights offering, strategic collaborations or grants and contracts.

Industry Context

The U.S. market for radiation sensitizing agents is experiencing dynamic growth through development of new radiation technology, the introduction of new agents, growth in the number of diagnosed patients in a variety of cancers and changes in treatment patterns.

Management Changes

Related Party Transactions

• The company entered into a manufacturing agreement with TCG GreenChem, Inc., where Dr. Chris Senanayake, an independent director, is CEO and CSO.
• The company issued a $250,000 promissory note to its Chief Executive Officer.
• The company entered into a securities purchase agreement with its Chief Executive Officer.

Stakeholder Impact

• Shareholders face the risk of stock dilution and potential delisting from Nasdaq.
• Employees face uncertainty due to the company's financial instability.
• The company's ability to develop and commercialize product candidates may be affected.

Next Steps

• The company must regain compliance with Nasdaq listing requirements by March 10, 2025, for stockholders equity and June 30, 2025, for minimum bid price.
• The company intends to complete a follow-on equity raise to bring the company's stockholders equity above the minimum requirement of $2.5 million.
• The company will continue to monitor the closing bid price of its common stock and may consider available options to regain compliance with the Minimum Bid Price Requirement.

Key Dates